<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221129056662N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-13</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation the pain prevention effect of different surgical techniques in laparoscopic cholecystectomy .</public_title>
      <acronym></acronym>
      <scientific_title>Pain preventive effects of different surgical techniques (low-pressure laparoscopy, intra operative ketorolac, and local bupivacaine administration) in female undergoing laparoscopic cholecystectomy.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-12-14</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67125</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: This is a double blinded RCT , Randomization description: Patients will randomly be divided into four groups,  The randomization will be done by an independent external researcher .Randomization will be done by Excel , Blinding description: After takking  informed consent, patients are randomly allocated into four groups .
patients wont  be informed about allocation . 
 data collector and  data assessor are unaware of allocation .
Only the surgeon knows allocation .</study_design>
      <phase>3</phase>
      <hc_freetext>laparoscopic cholecystectomy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: All the participants in this trial will go under laparoscopy with Co۲ pressure of ۱۵ mmHg except this group. This experimental group will experience a ۱۲ mmHg intra-abdominal CO۲ pressure . Intervention 2: Intervention group: The patients who would be allocated in this group will receive a concoction of bupivacaine ۲۰ mg( local anesthesia ) and dexamethasone ۸ mg. mixture will  be rubbed on the site of the removed gall bladder before the termination of the operation. Intervention 3: Intervention group: Participants in this group will receive a single ۳۰ mg IV ketorolac just before the surgery ends. Intervention 4: Control group: these patients will get standard protocol of laparoscopic surgery . all of participators will under go laparoscopic cholecystectomy with four-port technique .</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The data will be published after collection without mentioning personal data.

When:
After completing the study, the data will be accessible.

To whom:
The data will be accessible for researchers .

Conditions:
Using the results for planning  and conduct additional research .

Where to obtain:
babak۱۳۸۰@gmail.com
halimehg1378@gmail.com
xalirezasadeghix@gmail.com

How to obtain:
1month

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Babak Hosseine</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Chamran Blvd ، District 1 ، Hafez hospital</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>71946-34786</zip>
        <telephone>+98 71 3647 9531</telephone>
        <email>babak۱۳۸۰@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Babak Hosseine</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Chamran Blvd ، District 1 ، Hafez hospital</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>71946-34786</zip>
        <telephone>+98 71 3647 9531</telephone>
        <email>babak۱۳۸۰@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Pt should be female .
Age 18 - 65
BMI 18/5 - 30
ASA score I or II
Score that received from pain catastrophizing questionnaire should be less than 30 .
Patient should be without any underlying disease  .
Patient should be interested to participate in the study and complete the informed consent .</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Patient  is a smoker .
Patient take opium or opium component recently .
Enable to speak in Persian .
emergency surgery .
Previous history of hepatobiliary surgery .
Age less than 18 or more than 65 .
patients that is male .
Body mass index less than 18/5 or more than 30 .
Patients with underlying disease like HTN ، DM and other .
Patients with chronic diseases like liver failure ، renal failure ، respiratory disease ، heart problem and other .
Addiction to tobacco or alcohol .
Addiction to special drug .</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: All the participants in this trial will go under laparoscopy with Co۲ pressure of ۱۵ mmHg except this group. This experimental group will experience a ۱۲ mmHg intra-abdominal CO۲ pressure .</i_keyword>
      <i_keyword>Intervention group: The patients who would be allocated in this group will receive a concoction of bupivacaine ۲۰ mg( local anesthesia ) and dexamethasone ۸ mg. mixture will  be rubbed on the site of the removed gall bladder before the termination of the operation.</i_keyword>
      <i_keyword>Intervention group: Participants in this group will receive a single ۳۰ mg IV ketorolac just before the surgery ends.</i_keyword>
      <i_keyword>Control group: these patients will get standard protocol of laparoscopic surgery . all of participators will under go laparoscopic cholecystectomy with four-port technique .</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>This study is designed to evaluate the effect of pain prevention effect of different surgical technique in post op pain of laparoscopic cholecystectomy. these effects will be evaluated according to score that patients get from pain questionnaire . Timepoint: patients complete the pain questionnaire in first follow up visit. this is 7 days after discharging from hospital . Method of measurement: pain questionnaire.</prim_outcome>
      <prim_outcome>Patient ' s daily performance. Timepoint: patients completed daily performance questionnaire at the first follow up visit . this visit will be 7 days after discharging . Method of measurement: daily performance questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Dose of analgesic. Timepoint: during  discharge  from hospital . Method of measurement: physician 's order that prescribed during hospitalization .</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-12-04</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>iImam Hossein Sqe . Medical science university Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
